Company Encyclopedia
View More
name
Edgewise Therapeutics
EWTX.US
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
4.362 T
EWTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Edgewise Therapeutics Appoints Christopher Martin to Board

    Edgewise Therapeutics announced the appointment of Christopher Martin to its Board of Directors. Martin, a biotech executive, will aid in the company's commercial launch in Becker muscular dystrophy and cardiovascular asset advancement. Analysts rate EWTX stock as a Buy with a $30 target, despite Spark's AI Analyst rating it as Underperform due to high risks typical of early-stage biotech firms.

    Tip Ranks·
    US
    EWTX
    +1.89%
    Tip Ranks·
    US
    EWTX
    +1.89%

    Edgewise Therapeutics (EWTX) Gets a Buy from Evercore ISI

    Evercore ISI analyst Cory Kasimov maintains a Buy rating on Edgewise Therapeutics with a $30 price target. Shares closed at $22.26. Kasimov, a 5-star analyst, has a 16.6% average return. Edgewise has a Strong Buy consensus with a $37 price target, indicating a 66.22% upside. J.P. Morgan also rates it Buy with a $34 target.

    Tip Ranks·
    US
    EWTX
    +1.89%
    Tip Ranks·
    US
    EWTX
    +1.89%

    Edgewise Therapeutics shares are trading higher after JP Mprgan raised its price target on the stock from $33 to $34.

    benzinga_article·
    US
    EWTX
    +1.89%
    benzinga_article·
    US
    EWTX
    +1.89%

    Insider Moves: Edgewise Therapeutics Sees Major Stock Transactions!

    Edgewise Therapeutics saw significant insider transactions on November 13, 2025, with Director Jonathan C Fox purchasing 10,700 shares and CSO Alan J Russell selling 100,000 shares. The company appointed Michael Nofi as CFO and reported a Q3 net loss of $40.7 million. JPMorgan raised its price target to $33. Despite positive events, the stock is high-risk due to its pre-revenue stage and increasing losses. TipRanks’ AI Analyst rates EWTX as Underperform.

    Tip Ranks·
    US
    EWTX
    +1.89%
    Tip Ranks·
    US
    EWTX
    +1.89%

    Officer/Dir Russell Sells 100,000 ($2.1M) Of Edgewise Therapeutics Inc [EWTX]

    Russell Alan J, Officer and Director of Edgewise Therapeutics Inc [EWTX], filed a Form 4 on November 13, 2025, disclosing the sale of 100,000 shares at $21.12 each, totaling $2.1 million. Post-transaction, his direct holdings are 23,400 shares.

    Reuters·
    US
    EWTX
    +1.89%
    Reuters·
    US
    EWTX
    +1.89%